Compare DOMO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | DCTH |
|---|---|---|
| Founded | 2010 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 350.7M |
| IPO Year | 2018 | N/A |
| Metric | DOMO | DCTH |
|---|---|---|
| Price | $8.70 | $10.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $14.38 | ★ $22.60 |
| AVG Volume (30 Days) | ★ 1.0M | 596.1K |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $318,002,000.00 | $79,603,000.00 |
| Revenue This Year | $2.28 | $131.97 |
| Revenue Next Year | $2.45 | $38.84 |
| P/E Ratio | ★ N/A | $291.69 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $6.01 | $8.12 |
| 52 Week High | $18.49 | $18.23 |
| Indicator | DOMO | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 57.97 |
| Support Level | $8.55 | $9.84 |
| Resistance Level | $9.22 | $10.44 |
| Average True Range (ATR) | 0.53 | 0.43 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 9.34 | 55.56 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.